Matches in SemOpenAlex for { <https://semopenalex.org/work/W2591292302> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W2591292302 endingPage "464" @default.
- W2591292302 startingPage "464" @default.
- W2591292302 abstract "464 Background: Treatment of patients with RCC using IAL from a haploidentical donor (sibling/parent), without prior conditioning of the recipient, induced tumor regressions in 3/13 patients with minimal toxicity (Strair J Clin Onc 2003:3785). Responses were not detected until after 2-3 courses, consistent with an immunologic mechanism. We hypothesize that combining the angiogenesis inhibitor SU with IAL will improve outcomes given the potential immune stimulatory benefit of VEGF inhibition and the benefit from preventing clinical progression prior to the development of an immune response in patients with rapid disease progression. Single agent SU has a median PFS of 11mos and response rate of 31%. Methods: Eligible pts with measurable metastatic clear cell RCC, no prior systemic therapy, adequate organ function, no CNS met, and a suitable donor (≥2/6 HLA A, B, DR match, CMV-, HIV-, HepB/C-) received SU 50mg/day in a 4 wk on/2wk off schedule with IAL administration commencing at the start of cycle number 2 of SU. IAL was given once every 8-16 weeks. The primary objective of the study is to determine the PFS of the combination of SU and IAL in 35 patients for 80% power to detect an increase in median PFS from 11 to 18 months. Results: A pre-planned futility analysis was performed. To date 9 pts (7M/2F), median age 63 (range 49-74) have been treated with 29 cycles of DLI. Median number of DLI/pt 2(1-7). 5 pts discontinued DLI due to disease progression, 4 due to loss of donor availability. Median time to disease progression was 41 weeks (range 12-180 weeks), with 4 pts on study for >80 weeks. Response rate (CR+PR): 44% (1/9 CR, 3/9 PR, 2/9 SD, 3/9 PD). DLI was well tolerated with G2 fever in 1pt and G1 fever in 5 pts as the only DLI related AEs. SU related AE lead to SU dose reduction in 8/9 pts. Conclusions: Co-administration of SU and IAL is feasible and safe with no significant IAL related toxicity. Further study accrual is required to determine if SU plus IAL is superior to single agent SU. Clinical trial information: NCT00853125." @default.
- W2591292302 created "2017-03-03" @default.
- W2591292302 creator A5004027885 @default.
- W2591292302 creator A5019334641 @default.
- W2591292302 creator A5019788466 @default.
- W2591292302 creator A5057101315 @default.
- W2591292302 creator A5071773606 @default.
- W2591292302 creator A5074542465 @default.
- W2591292302 creator A5086350025 @default.
- W2591292302 creator A5090879940 @default.
- W2591292302 date "2013-02-20" @default.
- W2591292302 modified "2023-09-27" @default.
- W2591292302 title "Sunitinib (SU) plus extended courses of irradiated allogeneic lymphocytes (IAL) for patients with metastatic renal cell carcinoma (RCC)." @default.
- W2591292302 doi "https://doi.org/10.1200/jco.2013.31.6_suppl.464" @default.
- W2591292302 hasPublicationYear "2013" @default.
- W2591292302 type Work @default.
- W2591292302 sameAs 2591292302 @default.
- W2591292302 citedByCount "0" @default.
- W2591292302 crossrefType "journal-article" @default.
- W2591292302 hasAuthorship W2591292302A5004027885 @default.
- W2591292302 hasAuthorship W2591292302A5019334641 @default.
- W2591292302 hasAuthorship W2591292302A5019788466 @default.
- W2591292302 hasAuthorship W2591292302A5057101315 @default.
- W2591292302 hasAuthorship W2591292302A5071773606 @default.
- W2591292302 hasAuthorship W2591292302A5074542465 @default.
- W2591292302 hasAuthorship W2591292302A5086350025 @default.
- W2591292302 hasAuthorship W2591292302A5090879940 @default.
- W2591292302 hasConcept C126322002 @default.
- W2591292302 hasConcept C126894567 @default.
- W2591292302 hasConcept C141071460 @default.
- W2591292302 hasConcept C143998085 @default.
- W2591292302 hasConcept C203014093 @default.
- W2591292302 hasConcept C2777288759 @default.
- W2591292302 hasConcept C2777472916 @default.
- W2591292302 hasConcept C2779490328 @default.
- W2591292302 hasConcept C29730261 @default.
- W2591292302 hasConcept C71924100 @default.
- W2591292302 hasConcept C8891405 @default.
- W2591292302 hasConcept C90924648 @default.
- W2591292302 hasConceptScore W2591292302C126322002 @default.
- W2591292302 hasConceptScore W2591292302C126894567 @default.
- W2591292302 hasConceptScore W2591292302C141071460 @default.
- W2591292302 hasConceptScore W2591292302C143998085 @default.
- W2591292302 hasConceptScore W2591292302C203014093 @default.
- W2591292302 hasConceptScore W2591292302C2777288759 @default.
- W2591292302 hasConceptScore W2591292302C2777472916 @default.
- W2591292302 hasConceptScore W2591292302C2779490328 @default.
- W2591292302 hasConceptScore W2591292302C29730261 @default.
- W2591292302 hasConceptScore W2591292302C71924100 @default.
- W2591292302 hasConceptScore W2591292302C8891405 @default.
- W2591292302 hasConceptScore W2591292302C90924648 @default.
- W2591292302 hasIssue "6_suppl" @default.
- W2591292302 hasLocation W25912923021 @default.
- W2591292302 hasOpenAccess W2591292302 @default.
- W2591292302 hasPrimaryLocation W25912923021 @default.
- W2591292302 hasRelatedWork W1895933560 @default.
- W2591292302 hasRelatedWork W1994344097 @default.
- W2591292302 hasRelatedWork W2072245035 @default.
- W2591292302 hasRelatedWork W2171237277 @default.
- W2591292302 hasRelatedWork W2527810245 @default.
- W2591292302 hasRelatedWork W2544140097 @default.
- W2591292302 hasRelatedWork W2590524093 @default.
- W2591292302 hasRelatedWork W3151554875 @default.
- W2591292302 hasRelatedWork W4205243027 @default.
- W2591292302 hasRelatedWork W4205299447 @default.
- W2591292302 hasVolume "31" @default.
- W2591292302 isParatext "false" @default.
- W2591292302 isRetracted "false" @default.
- W2591292302 magId "2591292302" @default.
- W2591292302 workType "article" @default.